FDA advisory panel recommends peptide Semax be added to pharmacy compounding list

An FDA advisory panel has recommended that Semax, a synthetic peptide, be added to the US pharmacy compounding list, allowing licensed pharmacies to compound and dispense the drug. This regulatory shift expands access to a nootropic peptide previously unavailable through conventional pharmacy channels.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.